Stocktoria
BIO-TECHNE Corp TECH
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1989-02-09
BIO-TECHNE Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $1.1B | $931.0M |
| Gross profit | $790.3M | $769.7M | $769.8M | $756.5M | $632.9M |
| SG&A expense | $588.5M | $466.4M | $378.4M | $372.8M | $325.0M |
| Operating income | $102.3M | $206.7M | $298.9M | $296.6M | $237.3M |
| Interest expense | — | — | $11.2M | $11.3M | $14.0M |
| Income tax | $25.1M | $17.6M | $53.2M | $38.3M | $8.6M |
| Net income | $73.4M | $168.1M | $285.3M | $272.1M | $140.4M |
| EPS (diluted) | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 |
| Operating cash flow | $287.6M | $299.0M | $254.4M | $325.3M | $352.2M |
| Free cash flow | $256.6M | $236.1M | $216.1M | $280.4M | $307.9M |
| Cash & equivalents | $162.2M | $151.8M | $180.6M | $172.6M | $199.1M |
| Inventory | $189.4M | $179.7M | $171.6M | $141.1M | $116.7M |
| Total assets | $2.6B | $2.7B | $2.6B | $2.3B | $2.3B |
| Shareholders' equity | $1.9B | $2.1B | $2.0B | $1.7B | $1.6B |
Source: SEC EDGAR filings · CIK 0000842023 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.